Michael Sacerdote

Tonix Clinical Trial Will Succeed: 40 Years Of Medical Evidence

Editors' Note: This article covers stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Tonix Pharmaceuticals (NASDAQ:TNXP), which is developing a sublingual formulation of cyclobenzaprine known as TNX-102 SL for use in fibromyalgia and post-traumatic stress disorder, has enjoyed a powerful rally (partially catalyzed by an outstanding article by Joe Springer) with the stock rising from $8.50 to a peak of $21 in the past month. The entire investment thesis on TNXP lies in whether the pivotal phase 2b trial expecting results in October 2014 will succeed. In this article, I provide a digest of the medical literature relevant...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details